FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D	D.C. 20549
---------------	------------

Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMENT OF
obligations may continue. See Instruction 1(b).	Filed pursuant

CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* KLEIN JOSEPH III					2. Issuer Name and Ticker or Trading Symbol PDL BIOPHARMA, INC. [PDLI]									(Che	eck all ap	olicable) ctor		Owner	
(Last) (First) (Middle) C/O PDL BIOPHARMA, INC. 1400 SEAPORT BLVD.				3. Date of Earliest Transaction (Month/Day/Year) 05/20/2008										Officer (give title below)		Other (specify below)			
(Street) REDWO CITY (City)	C		94063 (Zip)		4. 11	4. If Amendment, Date of Original Filed (Month/Day/Year)) K Forr Forr	al or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person			
		Tab	le I - Nor	n-Deriv	ative	e Se	curit	es Ac	quired	, Dis	posed o	f, or	Bene	ficiall	y Own	ed			
			2. Transaction Date (Month/Day/Year)			2A. Deemed Execution Date, if any (Month/Day/Year)		3. 4. Secur Transaction Dispose Code (Instr. 5)					Secur Benef	icially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
								Code	v	Amount	t (A) or (D)		Price	Trans	action(s) 3 and 4)		(11150.4)		
Common Stock				05/20/2008		8			P ⁽¹⁾		500		Α	\$9.5	1	0,000	D		
Common	ommon Stock															1	I	By Trust	
Common	ommon Stock														10		I	By Wife	
		Ta	able II - [)								sed of, onvertib				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	prision pricise (Month/Day/Year) Execution Date, if any (Month/Day/Year) Execution Date, if any (Month/Day/Year) 8		4. Transa Code (8)	(Instr	n of Der Sec Acc (A) Dis of (posed D) str. 3, 4	Expiration (Month/I	Date Expiration Expiration Date (Month/Day/Year) Date Expiration Exercisable Date			Amount of Securities Underlying Derivative Security (Instr. and 4)		Price of erivative ecurity nstr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		

Explanation of Responses:

1. Purchase was made pursuant to a 10b5-1 plan established by the reporting person.

Remarks:

/s/ Francis Sarena by Francis Sarena, Attorney-in-Fact for

Joseph Klein III

05/20/2008

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.